Charles Gillham

Dr. Charles Gillham


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
AOAnita O'Donovan
Anita O'Donovan
MLMichelle Leech
Michelle Leech
CGCharles Gillham
Charles Gillham

1 January 2016 in British Journal of Radiology
Verified
Journal Article
Closed access
NLNaomi A Lavan
Naomi A Lavan
DKDara O Kavanagh
Dara O Kavanagh
JMJoseph Martin
Joseph Martin
CSCormac Small
Cormac Small
MJMyles R. Joyce
Myles R. Joyce
BOBrian D.P. O’neill
Brian D.P. O’neill
Purpose/Objective:Neoadjuvant 'long-course' chemoradiation is considered a standard of care in locally advanced rectal cancer. In addition to prostatectomy, external beam radiotherapy and brachytherapy with or without androgen suppression (AS) are well established in prostate cancer management. A retrospective review of ten cases was completed to explore the feasibility and safety of applying these standards in patients with dual pathology. To our knowledge this is the largest case series of synchronous rectal and prostate cancers treated with curative intent.Materials and Methods:Eligible patients had synchronous histologically proven locally advanced rectal cancer (defined as cT3-4Nx; cTxN1-2) and non-metastatic prostate cancer (pelvic nodal disease permissible). Curative treatment was delivered to both sites simultaneously. Follow up was per institutional guidelines. Acute and late toxicities were reviewed and a literature search performed.Results:Pelvic EBRT 45- 50.4Gy was delivered concurrent with 5-...

1 April 2008 in Clinical Oncology
Verified
Journal Article
Closed access
CGCharles Gillham
Charles Gillham
NAN. Aherne
N. Aherne
SRS. Rowley
S. Rowley
JMJ. Moore
J. Moore
DHD. Hollywood
D. Hollywood
JRJ.V. Reynolds
J.V. Reynolds

23 August 2007 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
CGCharles Gillham
Charles Gillham
JRJohn Reynolds
John Reynolds
DHDonal Hollywood
Donal Hollywood
A complete pathological response to neo-adjuvant chemo-radiation for oesophageal cancer is associated with favourable survival. However, such a benefit is seen in the minority. If one could identify, at diagnosis, those patients who were unlikely to respond unnecessary toxicity could be avoided and alternative treatment can be considered. The aim of this review was to highlight predictive markers currently assessed and evaluate their clinical utility.

1 January 2021 in BJR|Open
Verified
Journal Article
Open access
OHOrla Anne Houlihan
Orla Anne Houlihan
GRGuhan Rangaswamy
Guhan Rangaswamy
MDMary Dunne
Mary Dunne
CRChristine Rohan
Christine Rohan
LOLouise O'Neill
Louise O'Neill
OMOrla McArdle
Orla McArdle
Objective: Radiotherapy plays an important role in the management of lymphoma and many patients with lymphoma are cured with treatment. Risk of secondary malignancy and long-term cardiac and pulmonary toxicity from mediastinal radiotherapy exists. Delivery of radiotherapy using a deep inspiration breath-hold (DIBH) technique increases lung volume and has the potential to reduce dose to heart and lungs. We undertook a prospective study to assess the dosimetric differences in DIBH and free breathing (FB) plans in patients requiring mediastinal radiotherapy in clinical practice. Methods: We performed both FB and DIBH planning scans on 35 consecutive patients with mediastinal lymphoma needing radiotherapy. Contours and plans were generated for both data sets and dosimetric data were compared. All patients were planned using volumetric modulated arc therapy (VMAT). Data were compared for FB and DIBH plans with each patient acting as their own control using the related-samples Wilcoxon signed rank test. Results: DIBH significantly reduced lung doses (mean 10.6 vs 11.4Gy, p < 0.0005; V20 16.8 vs 18.3%, p = 0.001) and spinal cord maximum dose (20.6 vs 22.8Gy, p = 0.001). DIBH increased breast V4 (38.5% vs 31.8%, p = 0.006) and mean right breast dose (4.2 vs 3.6Gy, p = 0.010). There was no significant difference in heart doses when the entire study cohort was considered, however, mean heart dose tended to be lower with DIBH for upper mediastinal (UM) tumours (4.3 vs 4.9Gy, p = 0.05). Conclusion: Our study describes the potential benefit of DIBH in a population reflective of clinical practice. DIBH can decrease radiation dose to lungs, heart and spinal cord, however, may increase dose to breasts. DIBH is not always superior to FB, and the clinical significance of differences in dose to organs at risk in addition to the time required to treat patients with DIBH must be considered when deciding the most appropriate radiotherapy technique for each patient. Advances in knowledge: To our knowledge, this is the largest study comparing DIBH and FB planning for patients with lymphoma receiving mediastinal radiotherapy in clinical practice. It demonstrates the impact of an increasingly common radiotherapy technique on dose to organs at risk and the subsequent potential for long-term radiotherapy side-effects.

21 November 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
RGRichard Grainger
Richard Grainger
TTTatiana S. Temperley
Tatiana S. Temperley
HTHugo C Temperley
Hugo C Temperley
BCBen Creavin
Ben Creavin
EHEmily Harrold
Emily Harrold
MKMichael Eamon Kelly
Michael Eamon Kelly
Background: Colorectal cancer (CRC) mainly affects older adults, yet elderly patients are underrepresented in outcomes research. Accurate risk stratification tools, such as the Charlson Comorbidity Index (CCI), are essential for guiding surgical decisions in this group. Methods: We conducted a retrospective review of patients aged 75 years or older who underwent colorectal cancer resection at a tertiary centre between January 2019 and September 2024. Clinical, pathological, and molecular data were analyzed. The primary outcome was a composite of major postoperative complications (Clavien–Dindo grade 3 or higher) or 30-day mortality, stratified by CCI (5 or higher vs. less than 5). Statistical tests included chi-square, Fisher’s exact, and Mann–Whitney U as appropriate. Results: The median age was 81 years (range 75–97), with 59.7% male. CCI ≥ 5 was observed in 24.6% (51/211). The primary composite outcome of major postoperative complications or 30-day mortality occurred in 15/51 (29.4%) patients with a CCI ≥ 5 compared to 19/160 (11.9%) with a CCI < 5 (p = 0.04). Major complications occurred in 18.5% (39/211) of cases, and the 30-day mortality rate was 3.3% (7/211). Laparoscopic resection was independently protective in multivariate analysis (adjusted OR 0.37, p = 0.048), while age ≥85 and emergency presentation were not statistically significant predictors. Conclusions: Colorectal resection in patients aged ≥75 is linked with acceptable morbidity and low short-term death rates. A CCI ≥ 5 significantly predicts adverse outcomes and should be included in preoperative assessments. Minimally invasive surgery seems advantageous and should be considered, when possible, to enhance results in this high-risk group.